Probiotics and Its Associated Factors on Aflatoxin Biomarkers

Not Applicable

Completed

• Conditions: Aflatoxicosis
• Interventions: Other: Probiotics; Other: Placebo

• Registration Number: NCT03882294
• Lead Sponsor: Universiti Putra Malaysia

Brief Summary

The study will be aimed to investigate the effect of probiotic intervention and its associated factors on aflatoxin biomarkers among healthy subjects in Serdang and Kajang, Selangor

Detailed Description

The study will be a randomized, double-blind, placebo-controlled, parallel intervention that conducted for 12 weeks and followed-up for 4 weeks among healthy adults under living condition in Serdang and Kajang, Selangor. 164 subjects will be recruited for the intervention study, where 82 subjects will be randomly allocated to the probiotic or placebo group. Probiotic and placebo drinks (80 ml) will be prepared in the form of bottle. Placebo drink will have similar taste, colour, physical appearance, and nutritional value as probiotic drink but contain no LcS. Morning urine samples (15 ml), weight status, and dietary intake will be collected every two weeks from week 0 to week 12 and follow up until week 16 at community centre. Whereas, fasting blood samples (5 ml) and physical activity will be collected every four weeks for 16 weeks at the community centre.

Study Timeline

• Study First Submitted: 2019-03-14
• Study First Submitted QC: 2019-03-19
• Study First Posted: 2019-03-20
• Study Start: 2020-09-11
• Primary Completion: 2021-10-31
• Study Completion: 2021-10-31
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-15
• Last Update Posted: 2022-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

• Malaysian healthy male or female adults (BMI <30kg/m2) aged 20 to 60 years who have regular bowel movement (at least 4 times/week), AFB1 >4.71 pg/mg albumin, and AFM1 > 0.88 ng/ml

Exclusion Criteria

1. History or presence of any clinically important disease or disorder (eg. cardiovascular disease, kidney disease, diabetes mellitus, etc.) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
2. Mental status that is incompatible with the proper conduct of the study
3. Functional constipation [based on Rome III diagnostic criteria with a five-point symptoms based diagnosing tool (0=never or rarely, 1=sometimes, 2=often, 3=most of the time, 4=always)]
4. Diarrhoea within 2 months prior to the study start
5. Allergic reaction towards probiotic, milk and with gastric problem
6. Lactose intolerance
7. Use of medications or/and antibiotics
8. Use of probiotic, prebiotic and fibre supplements or/and laxatives during the two weeks prior to study start.
9. Drug/alcohol abuse (for alcohol 4 times/day or 20 times/week)
10. Pregnant
11. Reported special diets such as vegetarian, vegan, or macrobiotic
12. Festive (eg. Ramadan, Chinese New Year etc) 3 months before and during the study
13. Participation in another intervention study one month prior to the present study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Probiotics	Probiotics	Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10\^10 CFU/bottle (80 ml)
Placebo	Placebo	Subjects in placebo group will receive milk drink without LcS (80 ml).

Primary Outcome Measures

Name	Time	Method
Changes in serum AFB1-lysine adducts (pg/mg albumin) over 16 weeks	From week 0 to week 16	Analysis of serum AFB1-lysine adducts will be done using elisa kit through HPLC.
Changes in urinary AFM1 (ng/ml) over 16 weeks	From week 0 to week 16	Analysis of urinary AFM1 will be done using elisa kit.

Secondary Outcome Measures

Name	Time	Method
Changes in body mass index (kg/m^2) over 16 weeks	From week 0 to week 16	Changes in weight and height will be measured using weighing scale and body meter respectively. Weight and height will be combined to report BMI in kg/m\^2
Changes in waist circumference (cm) over 16 weeks	From week 0 to week 16	The parameter will be measured using measuring tape.
Changes in dietary intake over 16 weeks	From week 0 to week 16	Dietary assessment will be recorded via food frequency questionnaire (FFQ). The conversion of food frequency to the amount of food intake is carried out using the following formula: Amount of food (g/day) = frequency of intake (conversion factor) × serving size × total of serving × weight of food in one serving (Wessex Institute of Public Health, 1995).
Changes in knowledge, attitude and practice (KAP) on aflatoxin over 16 weeks	From week 0 to week 16	KAP will be examined using questionnaire in bilingual (English and Bahasa Malaysia). Knowledge towards aflatoxin is scored into two groups: know and do not know. Attitudes and practices are categorized using likert scale with 1=strongly disagree, 2=disagree, 3=agree and 4=strongly agree.
Changes in physical activity level (MET-min/week) over 16 weeks	From week 0 to week 16	The parameter will be examined using questionnaire based on the Global Physical Activity Questionnaire.

Trial Locations

Locations (1)

Teaching Hospital Universiti Putra Malaysia; 🇲🇾 Serdang, Malaysia